Article Text
Case Reports: Adverse drug reactions and complications
Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia
Abstract
The tyrosine kinase inhibitor dasatinib is approved for the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL). Patients on dasatinib can rarely develop a form of benign reversible reactive lymphadenopathy termed follicular lymphoid hyperplasia (FLH). Here, we describe a patient with Ph+ ALL who developed follicular lymphoma (FL) after prolonged treatment with dasatinib and who had complete remission of FL after discontinuation of dasatinib. This case suggests that dasatinib-associated FLH could be a premalignant condition that can transform into FL. Moreover, withdrawal of dasatinib may be sufficient for remission of dasatinib-associated FL.
- Dasatinib
- Haematology (incl blood transfusion)
- Oncology
- Tyrosine Kinase Inhibitor